Pfizer Price To Book vs. EBITDA

PFE Stock   12.40  0.02  0.16%   
Considering Pfizer's profitability and operating efficiency indicators, Pfizer Inc CDR may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Pfizer's ability to earn profits and add value for shareholders.
For Pfizer profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pfizer to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pfizer Inc CDR utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pfizer's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pfizer Inc CDR over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pfizer Inc CDR EBITDA vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Pfizer's current stock value. Our valuation model uses many indicators to compare Pfizer value to that of its competitors to determine the firm's financial worth.
Pfizer Inc CDR is considered to be number one stock in price to book category among its peers. It also is considered to be number one stock in ebitda category among its peers totaling about  11,775,340,837  of EBITDA per Price To Book. At this time, Pfizer's EBITDA is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Pfizer by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pfizer's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Pfizer EBITDA vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Pfizer

P/B

 = 

MV Per Share

BV Per Share

 = 
1.56 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Pfizer

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
18.37 B
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Pfizer EBITDA Comparison

Pfizer is currently under evaluation in ebitda category among its peers.

Pfizer Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Pfizer, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pfizer will eventually generate negative long term returns. The profitability progress is the general direction of Pfizer's change in net profit over the period of time. It can combine multiple indicators of Pfizer, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Interest Income-585 M-614.2 M
Interest Income1.6 B1.7 B
Operating Income3.4 B3.2 B
Net Income From Continuing Ops2.2 B2.1 B
Income Before Tax1.1 BB
Total Other Income Expense Net-1.7 B-1.6 B
Net Income Applicable To Common Shares36.1 B19.7 B
Net Income2.1 BB
Income Tax Expense3.8 BB
Change To Netincome-2.4 B-2.5 B

Pfizer Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Pfizer. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pfizer position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pfizer's important profitability drivers and their relationship over time.

Use Pfizer in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pfizer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will appreciate offsetting losses from the drop in the long position's value.

Pfizer Pair Trading

Pfizer Inc CDR Pair Trading Analysis

The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc CDR to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc CDR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Pfizer position

In addition to having Pfizer in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Corona Opportunity Thematic Idea Now

Corona Opportunity
Corona Opportunity Theme
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Pfizer Stock

To fully project Pfizer's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Pfizer Inc CDR at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Pfizer's income statement, its balance sheet, and the statement of cash flows.
Potential Pfizer investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Pfizer investors may work on each financial statement separately, they are all related. The changes in Pfizer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pfizer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.